Novacap supports Harmonic Pharma
Harmonic Pharma has developed an innovative scientific approach which aims at finding new therapeutic applications to existing molecules.
The innovative company, specialized in polypharmacology, identifies new apllications for existing molecules
Novacap supports Harmonic Pharma through a capital increase in order to finance its development and future projects.
Harmonic Pharma has developed a unique «pharmacological rediscovery ©» know-how based on polypharmacology. This innovative scientific approach aims to find new therapeutic applications to existing molecules.
Beyond pharmaceutical applications, Harmonic Pharma’s know-how can also be applied in other areas, such as in cosmetics where Novacap and Harmonic Pharma have also decided to partner together.
The support of Novacap will allow Harmonic Pharma to pursue several repositioning programs, particularly in oncology
Harmonic Pharma has developed an integrated technological platform that defines the polypharmacological profile of active ingredients in order to find new biological targets to active ingredients that are well tolerated by humans. This alliance results from a shared vision around the optimization of existing molecules. The support of Novacap will allow Harmonic Pharma to pursue several repositioning programs, particularly in oncology
The access to Harmonic Pharma’s technology broadens Novacap’s services offering to its customers. This alliance is fully aligned with our group’s strategy that seeks to enhance our technological and polypharmacological portfolios. Harmonic Pharma’s platform increases the chances of success of preclinical and clinical studies by selecting molecules whose toxicological profile is already well documented
About Harmonic Pharma
Harmonic Pharma’s core business is based on the new paradigm of polypharmacology. This new paradigm consists in identifying the ensemble of biological targets linked to safe compounds in order to investigate their novel therapeutic applications. As an example, HPH112, developed in collaboration with the Institut Curie in Paris, is a promising drug candidate in combination with recent oncology treatments. In addition, the company offers its Pharmacological Rediscovery© platform to its partners/clients in health applications.